Amneal Pharmaceuticals vs Elanco
Add, change or remove companies; up to four.
The short version
- Elanco is the larger business, with $4.7B of revenue in fiscal 2025 against $3.0B for Amneal Pharmaceuticals, about 1.6 times as much.
- Amneal Pharmaceuticals grew revenue faster (8.1%, against 6.2%).
- Amneal Pharmaceuticals turned more of its sales into free cash flow (8.9% FCF margin, against 6.0%).
- Amneal Pharmaceuticals earned a higher return on the capital invested in it (16.1%, against −0.1%).
| Latest fiscal year | AMRX · FY25 | ELAN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $6.7B | $11.4B |
| Revenue | $3.0B | $4.7B |
| Free cash flow | $270M | $284M |
| Net income | $72.1M | −$232M |
| Growth | ||
| Revenue growth | 8.1% | 6.2% |
| 5-year growth | 8.7% | 7.6% |
| Share count change | 5.1% | −0.2% |
| Profitability | ||
| Gross margin | 36.9% | 55.0% |
| Operating margin | 13.1% | — |
| Net margin | 2.4% | −4.9% |
| FCF margin | 8.9% | 6.0% |
| Return on capital | 16.1% | −0.1% |
| Return on equity | — | −3.7% |
| Balance sheet | ||
| Net debt | $2.3B | $3.5B |
| Net debt / EBITDA | 3.8x | 5.2x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 41.6x | — |
| Piotroski F-score | 7 | 6 |
FY16
AMRX $1.0B
ELAN $2.9B
FY17
AMRX $1.0B
ELAN $2.9B
FY18
AMRX $1.7B
ELAN $3.1B
FY19
AMRX $1.6B
ELAN $3.1B
FY20
AMRX $2.0B
ELAN $3.3B
FY21
AMRX $2.1B
ELAN $4.8B
FY22
AMRX $2.2B
ELAN $4.4B
FY23
AMRX $2.4B
ELAN $4.4B
FY24
AMRX $2.8B
ELAN $4.4B
FY25
AMRX $3.0B
ELAN $4.7B
AMRX
ELAN
FY16
AMRX 28.0%
ELAN —
FY17
AMRX 23.7%
ELAN —
FY18
AMRX −1.2%
ELAN —
FY19
AMRX −15.3%
ELAN —
FY20
AMRX 4.6%
ELAN —
FY21
AMRX 7.3%
ELAN —
FY22
AMRX −4.3%
ELAN —
FY23
AMRX 8.5%
ELAN —
FY24
AMRX 8.9%
ELAN —
FY25
AMRX 13.1%
ELAN —
AMRX
ELAN
FY16
AMRX −$7.7M
ELAN $45.6M
FY17
AMRX $139M
ELAN $75.2M
FY18
AMRX $167M
ELAN $353M
FY19
AMRX −$45.5M
ELAN $84.0M
FY20
AMRX $323M
ELAN −$176M
FY21
AMRX $194M
ELAN $324M
FY22
AMRX $18.7M
ELAN $281M
FY23
AMRX $302M
ELAN $131M
FY24
AMRX $243M
ELAN $394M
FY25
AMRX $270M
ELAN $284M
AMRX
ELAN
FY16
AMRX —
ELAN —
FY17
AMRX —
ELAN —
FY18
AMRX −0.7%
ELAN 1.5%
FY19
AMRX −6.3%
ELAN 1.9%
FY20
AMRX 2.5%
ELAN −3.9%
FY21
AMRX 3.4%
ELAN −1.9%
FY22
AMRX −2.6%
ELAN 1.0%
FY23
AMRX 6.2%
ELAN −5.9%
FY24
AMRX 8.5%
ELAN 5.0%
FY25
AMRX 16.1%
ELAN −0.1%
AMRX
ELAN
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.